Observing Platelet Activability in a Once daily vs. a More frequent Aspirin intake regimen - OPA- & OMA-trial

Vrije Universiteit Medisch Centrum0 个研究点目标入组 35 人开始时间: 待定最近更新: 2024年6月11日

适应症

试验速览

Trial is onging in other countries

•- Outpatients being treated for stable cardiovascular disease by the cardiology department.
•- Stable cardiovascular disease defined as: coronary artery disease, peripheral vascular disease or previous myocardial infarction.
•- Intake of 80 mg of acetylsalicylic acid once a day

•- Active bleeding
•- Diabetes mellitus
•- Thrombocytopenia
•- Thrombocytosis
•- Valvualar heart disease/dysfunction
•- Thrombopathy (e.g. von Willebrand disease, Glanzmann*s thrombasthenia and Bernard-Soulier syndrome) ;
•- Any ischemic event or revascularization procedure (percutaneous coronary intervention or coronary artery bypass grafting) within the last six months;
•- Alcohol intake the day before blood sampling;
•- Non-compliance to the protocol ;
•- Baxter rolls (i.e. presorted medicine by a pharmacist) ;
•- Recent use of antiplatelet drugs, anticoagulants or drugs that are known to alter platelet function, other than aspirin (e.g. NSAID*s, tirofiban, eptifibatide, abciximab, beta-lactam antibiotics, dextran, SSRI*s, clomipramine & amitriptyline, dipyridamole, verapamil, diltiazem , ginkgo biloba, ginseng, St John*s wort). ;

发起方